Duration of androgen suppression in the treatment of prostate cancer

Autor: Bolla , Michel, De Reijke , Theodorus M, Van Tienhoven , Geertjan, Van Den Bergh , Alphonsus C M, Oddens , Jorg, Poortmans , Philip M P, Gez , Eliahu, Kil , Paul, Akdas , Atif, Soete , Guy, Kariakine , Oleg, Van Der Steen-Banasik , Elsbietha M, Musat , Elena, Piérart , Marianne, Mauer , Murielle E, Collette , Laurence, Renseigné , Non, Bosset , Jean-François

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2009, 360 (24), pp.2516-2527. 〈10.1056/NEJMoa0810095〉
New England Journal of Medicine, Massachusetts Medical Society, 2009, 360 (24), pp.2516-2527. ⟨10.1056/NEJMoa0810095⟩
New England Journal of Medicine, 360(24), 2516-2527. MASSACHUSETTS MEDICAL SOC
New England journal of medicine, 360(24), 2516-2527. Massachussetts Medical Society

International audience; BACKGROUND: The combination of radiotherapy plus long-term medical suppression of androgens (> or = 2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use of radiotherapy plus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d32d2531b6803c4526344e7fb938e50
https://hal.archives-ouvertes.fr/hal-00492521